Abstract
The donation of hematopoietic progenitor cells (HPC), either through bone marrow or apheresis, is a common option for the treatment of onco-hematological diseases. Although it is considered a safe procedure, adverse reactions are expected. Considering the protection of the donors, the global trend is to register the adverse events in a database like the World Marrow Donor Association, Net…